Resumen
This review explores the use of hematopoietic stem cell transplantation (HSCT) as a treatment option for chronic myeloid leukemia (CML) patients. While CML treatment has greatly improved with tyrosine kinase inhibitors (TKIs), some patients do not respond well or reach advanced disease stages. The goal now is to achieve treatment-free remission (TFR). Although discontinuing TKIs shows promise, relapse risk is high. This review discusses recent advances in HSCT and its role in CML treatment, suggesting it should be considered early in disease management to enhance the chances of achieving TFR alongside TKIs.